



Cancer Therapy Pathways program



With the rapid approval of new cancer treatments and the increasing cost of care, the goal of our Therapy Pathways program is to enhance both the quality and value of care for our members. We identify anti-cancer regimens supported by evidence-based guidelines, such as the clinical benefit (efficacy) and side-effect profile (toxicity). Among regimens with comparable efficacy and toxicity, we give additional consideration to the frequency of hospitalizations during therapy, duration of therapy, drug costs and total cost of care.



Please remember that this program isn't a substitute for the provider's therapy recommendation or care decision made between the provider and patient. Participating providers must use independent medical judgment in the context of individual clinical circumstances to determine a patient's care or treatment.

Symbol definitions

 In combination with  Alone or in combination with  Followed by

Table of contents

Please note that the therapy regimens within each of these programs are in no particular order of preference. You may use any of the therapy regimens within each program.

Bladder Cancer	3
Breast Cancer	4
Chronic Lymphocytic Leukemia/Small Lymphocytic (CLL/SLL).....	7
Chronic Myeloid Leukemia (CML).....	8
Colon/Rectal Cancer	9
Endometrial Carcinoma	11
Esophageal and Esophagogastric Cancers	12
Gastric Cancer.....	14
Head and Neck Cancer	16
Hepatobiliary Cancer.....	17
Kidney Cancer	18
Lung Cancer, Non-Small Cell	19
Lung Cancer, Small Cell	22
Lymphoma, Classic Hodgkin	23
Lymphoma, Diffuse Large B-cell	24
Lymphoma, Follicular	25
Lymphoma, Mantle Cell	26
Lymphoma, Marginal Zone	27
Melanoma	28
Multiple Myeloma.....	29
Ovarian, Fallopian and Primary Peritoneal Cancer	30
Pancreatic Cancer	31
Prostate Cancer	32
List of updates	33

This section summarizes the updates to the program since it began in 2020.

To request a list of reference documentation, please email unitedoncology@uhc.com.

Bladder Cancer (Non-Muscle Invasive): Neoadjuvant/Adjuvant

- Intravesical BCG (Bacillus Calmette-Guerin)
- Intravesical Gemcitabine

Bladder Cancer (Muscle Invasive): Neoadjuvant/Adjuvant

- Gemcitabine + Cisplatin
- Nivolumab (adjuvant only)

Bladder Cancer: Radiosensitizing Chemotherapy for Organ-Preserving Chemoradiation

- Cisplatin + Fluorouracil (5FU)
- Gemcitabine

Bladder Cancer: Locally Advanced or Metastatic: 1st Line of Therapy

- Gemcitabine + Cisplatin or Carboplatin
- Enfortumab vedotin-ejfv + Pembrolizumab

Bladder Cancer: Locally Advanced or Metastatic: Maintenance Post 1st Line of Therapy and No Progression

- Avelumab
- Enfortumab vedotin-ejfv + Pembrolizumab

Bladder Cancer: Locally Advanced or Metastatic: 2nd + Subsequent Lines of Therapy

- Avelumab (if IO not used previously)
- Gemcitabine + Cisplatin or Carboplatin (if platinum-based therapy not used previously)
- Enfortumab vedotin-ejfv
- Erdafitinib (FGFR3 mutation positive)
- Nivolumab (if IO not used previously)
- Pembrolizumab (if IO not used previously)

Breast Cancer: Neoadjuvant/Adjuvant

HER2 NEGATIVE:

- Docetaxel + Cyclophosphamide (TC)
- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel every 2 weeks (ddAC → q2w T)
- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel weekly (ddAC → weekly T)
- Olaparib (for BRCA 1/2 mutation positive; adjuvant therapy only)
- Pembrolizumab + Carboplatin + Paclitaxel → Pembrolizumab + Cyclophosphamide + Doxorubicin or Epirubicin → adjuvant Pembrolizumab (for high-risk TNBC only)

HER2 POSITIVE:

- Docetaxel + Carboplatin + Trastuzumab* (TCH)
- Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCHP) (stage IIA+)
- Doxorubicin + Cyclophosphamide → Paclitaxel weekly + Trastuzumab* (AC → TH)
- Paclitaxel + Trastuzumab*

Breast Cancer: Adjuvant (Residual Disease Post-Neoadjuvant Treatment)

TRIPLE NEGATIVE BREAST CANCER:

- Capecitabine
- Pembrolizumab (continuation in TNBC following Pembrolizumab + chemotherapy)

HER2 POSITIVE:

- Ado-trastuzumab Emtansine (T-DM1)
- Trastuzumab

Breast Cancer: Metastatic and Recurrent – Endocrine Therapy

HER2 NEGATIVE:

1st Line of Therapy

- Anastrozole + Abemaciclib
- Anastrozole + Palbociclib
- Exemestane + Abemaciclib
- Exemestane + Palbociclib
- Fulvestrant + Anastrozole
- Fulvestrant + Letrozole
- Inavolisib + palbociclib + fulvestrant (PIK3CA activating mutations)
- Letrozole + Abemaciclib
- Letrozole + Palbociclib

1st + Subsequent Lines of Therapy

- Anastrozole
- Exemestane
- Fulvestrant
- Letrozole
- Tamoxifen

2nd + Subsequent Lines of Therapy

- Anastrozole
- Exemestane
- Fulvestrant
- Fulvestrant + Abemaciclib
- Fulvestrant + Palbociclib
- Letrozole
- Tamoxifen

Breast Cancer: Neoadjuvant/Adjuvant

HER2 NEGATIVE:

- Docetaxel + Cyclophosphamide (TC)
- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel every 2 weeks (ddAC → q2w T)
- Doxorubicin + Cyclophosphamide (dose dense) → Paclitaxel weekly (ddAC → weekly T)
- Olaparib (for BRCA 1/2 mutation positive; adjuvant therapy only)
- Pembrolizumab + Carboplatin + Paclitaxel → Pembrolizumab + Cyclophosphamide + Doxorubicin or Epirubicin → adjuvant Pembrolizumab (for high-risk TNBC only)

HER2 POSITIVE:

- Docetaxel + Carboplatin + Trastuzumab* (TCH)
- Doxorubicin + Cyclophosphamide → Paclitaxel weekly + Trastuzumab* (AC → TH)
- Paclitaxel + Trastuzumab*

Breast Cancer: Adjuvant (Residual Disease Post-Neoadjuvant Treatment)

TRIPLE NEGATIVE BREAST CANCER:

- Capecitabine
- Pembrolizumab (continuation in TNBC following Pembrolizumab + chemotherapy)

HER2 POSITIVE:

- Ado-trastuzumab Emtansine (T-DM1)
- Trastuzumab

Breast Cancer: Metastatic and Recurrent – Endocrine Therapy

HER2 NEGATIVE:

1st Line of Therapy

- Anastrozole + Abemaciclib
- Anastrozole + Palbociclib
- Exemestane + Abemaciclib
- Exemestane + Palbociclib
- Fulvestrant + Anastrozole
- Fulvestrant + Letrozole
- Letrozole + Abemaciclib
- Letrozole + Palbociclib

1st + Subsequent Lines of Therapy

- Anastrozole
- Exemestane
- Fulvestrant
- Letrozole
- Tamoxifen

2nd + Subsequent Lines of Therapy

- Anastrozole
- Exemestane
- Fulvestrant
- Fulvestrant + Abemaciclib
- Fulvestrant + Palbociclib
- Letrozole
- Tamoxifen

Breast Cancer: Metastatic and Recurrent – Chemotherapy

HER2 NEGATIVE:

1st + Subsequent Lines of Therapy

- Capecitabine
- Carboplatin (Germline BRCA 1/2 mutation positive and TNBC)
- Cisplatin (Germline BRCA 1/2 mutation positive and TNBC)
- Docetaxel
- Doxorubicin
- Fam-trastuzumab deruxtecan--nxki (2nd + subsequent lines of therapy for HER2 IHC 1+ or 2+ and ISH negative, HR+ or mTNBC)
- Gemcitabine
- Olaparib (Germline BRCA 1/2 mutation positive)
- Paclitaxel
- Pembrolizumab + Gemcitabine + Carboplatin (mTNBC and PD-L1 expression threshold for positivity combined positive score ≥ 10)
- Pembrolizumab + Paclitaxel (mTNBC and PD-L1 expression threshold for positivity combined positive score ≥ 10)
- Sacituzumab Govitecan-hziy (2nd + subsequent lines of therapy for mTNBC and 3rd + subsequent lines of therapy for HR+, HER2-)
- Vinorelbine

HER2 POSITIVE:

1st Line of Therapy

- Docetaxel + Trastuzumab* + Pertuzumab
- Paclitaxel + Trastuzumab* + Pertuzumab

1st + subsequent lines of therapy

- AI + Trastuzumab (HR+)
- AI + Lapatinib (HR+)

2nd + Subsequent Lines of Therapy

- Fam-trastuzumab deruxtecan-nxki
- Tucatinib + Trastuzumab* + Capecitabine (in patients with brain mets)

3rd + Subsequent Lines of therapy

- Tucatinib + Trastuzumab* + Capecitabine
- Ado-trastuzumab emtansine

4th + subsequent lines of therapy

- Trastuzumab + Paclitaxel
- Trastuzumab + Vinorelbine
- Trastuzumab + Gemcitabine
- Trastuzumab + Capecitabine

* Kanjinti® and Trazimera® are the preferred medications for UnitedHealthcare commercial plans. Kanjinti is preferred for UnitedHealthcare Community Plan in most markets. Kanjinti, Trazimera and trastuzumab are preferred for UnitedHealthcare® Medicare Advantage plan.

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

1st line of therapy

- Acalabrutinib
- Bendamustine + Rituximab* (without del(17p)/TP53 mutation)
- Ibrutinib
- Venetoclax + Obinutuzumab

2nd + Subsequent lines of therapy

- Acalabrutinib
- Bendamustine + Rituximab* (without del(17p)/TP53 mutation)
- Ibrutinib
- Venetoclax + Rituximab*

*Truxima and Ruxience are the preferred products for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Truxima, Ruxience and rituximab are preferred for UnitedHealthcare Medicare Advantage plan.

[Back to home](#) >

Chronic Myeloid Leukemia (CML)

1st line of therapy

- Imatinib

2nd + Subsequent lines of therapy

- Asciminib (T315I only)
- Imatinib
- Nilotinib

Colon/Rectal Cancer: Adjuvant

- Capecitabine + Oxaliplatin (CAPEOX)
- Fluorouracil (5-FU)/Leucovorin
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX)

Colon/Rectal Cancer: Metastatic KRAS/NRAS/BRAF: Unknown/Mutant 1st and Subsequent Lines of Therapy

- Capecitabine
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) +/- Bevacizumab*
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) +/- Bevacizumab*
- Fluorouracil + Leucovorin +/- Bevacizumab*

Colon/Rectal Cancer: Metastatic KRAS/NRAS/BRAF: Wild Type 1st + Subsequent Lines of Therapy

- Capecitabine
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) + Cetuximab
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) + Panitumumab
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) +/- Bevacizumab*
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) + Cetuximab
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) + Panitumumab
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) +/- Bevacizumab*
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX)+ Encorafenib + Panitumumab or Cetuximab* (BRAF V600E mut+; 1st line only)
- Fluorouracil + Leucovorin +/- Bevacizumab*

3rd + Subsequent Lines of Therapy

- Trifluridine + Tipiracil + Bevacizumab* (KRAS/NRAS/BRAF mutation positive, unknown, or Wild Type)

* Mvasi® is the preferred medication for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Mvasi and bevacizumab are preferred for UnitedHealthcare Medicare Advantage plan.

Colon/Rectal Cancer: Metastatic MSI-H/dMMR or POLE/POLD1 mutation

1st Line of Therapy

- Nivolumab + Ipilimumab followed by Nivolumab maintenance
- Pembrolizumab

2nd + Subsequent Lines of Therapy

- Capecitabine
- Encorafenib + Cetuximab (BRAF V600E mutation positive)
- Encorafenib + Panitumumab (BRAF V600E mutation positive)
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) + Cetuximab
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) + Panitumumab
- Fluorouracil + Leucovorin + Irinotecan (FOLFIRI) +/- Bevacizumab*
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) + Cetuximab
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) + Panitumumab
- Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX) +/- Bevacizumab*
- Fluorouracil + Leucovorin +/- Bevacizumab*

3rd + Subsequent Lines of Therapy

- Trifluridine + Tipiracil + Bevacizumab*

Endometrial Carcinoma: Adjuvant

- Carboplatin + Paclitaxel
- Carboplatin + Paclitaxel + Dostarlimab-gxly (stage III-IV tumors)

Endometrial Carcinoma: Metastatic or Recurrent

1st Line of Therapy

- Carboplatin + Paclitaxel
- Carboplatin + Paclitaxel + Dostarlimab-gxly (for patients who are ICI naïve)
- Carboplatin + Paclitaxel + Trastuzumab (for stage III/IV or recurrent HER2-positive uterine serous carcinoma only)
- Lenvatinib + Pembrolizumab (for pMMR tumors after prior platinum-based therapy, including neoadjuvant and adjuvant)

Esophageal and Esophagogastric Cancers

Preoperative or Definitive chemoradiotherapy

- Capecitabine + Cisplatin + Radiotherapy
- Capecitabine + Oxaliplatin + Radiotherapy
- Fluorouracil ± Leucovorin + Cisplatin + Radiotherapy
- Fluorouracil ± Leucovorin + Oxaliplatin + Radiotherapy
- Paclitaxel + Carboplatin + Radiotherapy

Perioperative

- Capecitabine + Cisplatin
- Capecitabine + Oxaliplatin
- Fluorouracil + Leucovorin + Oxaliplatin + Docetaxel (FLOT)
- Fluorouracil ± Leucovorin + Cisplatin
- Fluorouracil ± Leucovorin + Oxaliplatin

Recurrent/Metastatic/Unresectable locally advanced disease; 1st line of therapy

HER2-negative or Unknown

- Capecitabine + Cisplatin
- Capecitabine + Cisplatin + Nivolumab (squamous cell carcinoma and CPS ≥ 1)
- Capecitabine + Oxaliplatin
- Capecitabine + Oxaliplatin + Nivolumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Capecitabine + Cisplatin + Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Capecitabine + Oxaliplatin + Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Capecitabine + Cisplatin + Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Capecitabine + Oxaliplatin + Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Fluorouracil ± Leucovorin + Cisplatin
- Fluorouracil ± Leucovorin + Cisplatin + Nivolumab (squamous cell carcinoma and CPS ≥ 1)
- Fluorouracil ± Leucovorin + Oxaliplatin
- Fluorouracil ± Leucovorin + Oxaliplatin + Nivolumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Fluorouracil ± Leucovorin + Cisplatin + Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Fluorouracil ± Leucovorin + Oxaliplatin + Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Fluorouracil ± Leucovorin + Cisplatin + Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Fluorouracil ± Leucovorin + Oxaliplatin + Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1)
- Cisplatin or Oxaliplatin + Paclitaxel + Tislelizumab (squamous cell carcinoma CPS ≥ 1)

HER2-positive

- Capecitabine + Cisplatin + Trastuzumab
- Capecitabine + Oxaliplatin + Trastuzumab
- Capecitabine + Cisplatin + Trastuzumab + Pembrolizumab (CPS \geq 1)
- Capecitabine + Oxaliplatin + Trastuzumab + Pembrolizumab (CPS \geq 1)
- Fluorouracil \pm Leucovorin + Cisplatin + Trastuzumab
- Fluorouracil \pm Leucovorin + Oxaliplatin + Trastuzumab
- Fluorouracil \pm Leucovorin + Cisplatin + Trastuzumab + Pembrolizumab (CPS \geq 1)
- Fluorouracil \pm Leucovorin + Oxaliplatin + Trastuzumab + Pembrolizumab (CPS \geq 1)

Recurrent/Metastatic/Unresectable locally advanced disease; 2nd + subsequent lines of therapy

- Docetaxel
- Fam-trastuzumab deruxtecan-nxki (for HER2-positive adenocarcinoma only)
- Irinotecan
- Paclitaxel
- Paclitaxel + Ramucirumab (for adenocarcinoma)

Gastric Cancer

Perioperative

- Capecitabine + Oxaliplatin
- Fluorouracil + Leucovorin + Oxaliplatin + Docetaxel (FLOT)
- Fluorouracil ± Leucovorin + Cisplatin
- Fluorouracil ± Leucovorin + Oxaliplatin

Postoperative chemotherapy or chemoradiotherapy

- Capecitabine + Oxaliplatin
- Capecitabine ± Radiotherapy
- Fluorouracil ± Radiotherapy

Recurrent/Metastatic/Unresectable locally advanced disease; 1st line of therapy

HER2-negative or Unknown

- Capecitabine + Cisplatin or Oxaliplatin
- Capecitabine + Oxaliplatin + Nivolumab (for PD-L1 CPS ≥ 5)
- Capecitabine + Cisplatin or Oxaliplatin + Pembrolizumab (PD-L1 CPS ≥ 5)
- Capecitabine + Cisplatin or Oxaliplatin + Tislelizumab (PD-L1 CPS ≥ 5)
- Fluorouracil ± Leucovorin + Cisplatin or Oxaliplatin
- Fluorouracil ± Leucovorin + Oxaliplatin + Nivolumab (for PD-L1 CPS ≥ 5)
- Fluorouracil ± Leucovorin + Cisplatin or Oxaliplatin + Pembrolizumab (PD-L1 CPS ≥ 5)
- Fluorouracil ± Leucovorin + Cisplatin or Oxaliplatin + Tislelizumab (PD-L1 CPS ≥ 5)

HER2-positive

- Capecitabine + Cisplatin + Trastuzumab
- Capecitabine + Cisplatin + Trastuzumab + Pembrolizumab (CPS ≥ 1)
- Capecitabine + Oxaliplatin + Trastuzumab
- Capecitabine + Oxaliplatin + Trastuzumab + Pembrolizumab (CPS ≥ 1)
- Fluorouracil ± Leucovorin + Cisplatin + Trastuzumab
- Fluorouracil ± Leucovorin + Cisplatin + Trastuzumab + Pembrolizumab (CPS ≥ 1)
- Fluorouracil ± Leucovorin + Oxaliplatin + Trastuzumab
- Fluorouracil ± Leucovorin + Oxaliplatin + Trastuzumab + Pembrolizumab (CPS ≥ 1)

Recurrent/Metastatic/Unresectable locally advanced disease; 2nd + subsequent lines of therapy

- Docetaxel
- Fam-trastuzumab deruxtecan-nxki (for HER2-positive adenocarcinoma only)
- Irinotecan
- Paclitaxel
- Paclitaxel + Ramucirumab (for adenocarcinoma)

Head and Neck Cancer: Primary Definitive Therapy

Non-Nasopharyngeal

- Cisplatin + Concurrent Radiation Therapy

Nasopharyngeal

- Cisplatin + Concurrent Radiation Therapy
- Cisplatin + Gemcitabine

Head and Neck Cancer: Adjuvant Therapy

Non-Nasopharyngeal

- Cisplatin + Concurrent Radiation Therapy

Nasopharyngeal

- Carboplatin + Fluorouracil (5FU)
- Cisplatin + Fluorouracil (5FU)

Head and Neck Cancer: Recurrent/Metastatic/Unresectable

Non-Nasopharyngeal: 1st Line of Therapy

- Carboplatin + Paclitaxel + Pembrolizumab
- Cisplatin + Fluorouracil (5FU)
- Cisplatin or Carboplatin + Docetaxel
- Cisplatin or Carboplatin + Fluorouracil (5FU) + Cetuximab
- Cisplatin or Carboplatin + Fluorouracil (5FU) + Pembrolizumab
- Cisplatin or Carboplatin + Paclitaxel
- Pembrolizumab (for combined positive score (CPS) ≥ 1 only)

Non-Nasopharyngeal: Maintenance

- Cetuximab
- Pembrolizumab (for combined positive score (CPS) ≥ 1 only)

Non-Nasopharyngeal: 2nd + Subsequent Lines of Therapy

- Cisplatin + Fluorouracil (5FU)
- Cisplatin or Carboplatin + Docetaxel
- Cisplatin or Carboplatin + Fluorouracil (5FU) + Cetuximab
- Cisplatin or Carboplatin + Paclitaxel
- Nivolumab (if IO not used previously)
- Pembrolizumab (if IO not used previously)

Nasopharyngeal: 1st Line of Therapy

- Cisplatin + Gemcitabine
- Cisplatin + Gemcitabine + Toripalimab-tpzi

Hepatobiliary Cancer

Hepatocellular Carcinoma: Unresectable, Not a Transplant Candidate, Metastatic Disease, Inoperable by PS or Comorbidity

1st Line of Therapy

- Atezolizumab + Bevacizumab*
- Durvalumab
- Tremelimumab-actl + Durvalumab

Biliary Tract Cancers (Gallbladder, Intrahepatic and Extrahepatic Cholangiocarcinoma): Adjuvant Therapy

- Capecitabine

Biliary Tract Cancers (Gallbladder, Intrahepatic and Extrahepatic Cholangiocarcinoma): Unresectable/Metastatic

1st Line of Therapy

- Gemcitabine + Cisplatin
- Gemcitabine + Cisplatin + Durvalumab
- Gemcitabine + Cisplatin + Pembrolizumab

2nd + Subsequent Lines of Therapy

- Fluorouracil/Leucovorin + Oxaliplatin (FOLFOX)
- Ivosidenib (in IDH1 Mutation Cholangiocarcinoma)

* Mvasi is the preferred medication for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Mvasi and bevacizumab are preferred for UnitedHealthcare Medicare Advantage plan.

[Back to home](#) >

Kidney Cancer

Adjuvant

- Pembrolizumab

Relapsed or Metastatic (Clear Cell): 1st Line of Therapy

- Axitinib + Avelumab
- Axitinib + Pembrolizumab
- Cabozantinib + Nivolumab
- Lenvatinib + Pembrolizumab
- Ipilimumab + Nivolumab

Lung Cancer, Non-Small Cell: Neoadjuvant/Adjuvant

Nonsquamous

- Alectinib (ALK rearrangement positive; adjuvant only)
- Carboplatin + Paclitaxel ± Concurrent Radiation Therapy (RT)
- Carboplatin + Pemetrexed ± Concurrent Radiation Therapy (RT)
- Cisplatin + Etoposide + Concurrent Radiation Therapy (RT)
- Cisplatin + Pemetrexed ± Concurrent Radiation Therapy (RT)
- Cisplatin + Vinorelbine
- Nivolumab + Cisplatin + Docetaxel (Neoadjuvant only)
- Nivolumab + Carboplatin + Paclitaxel (Neoadjuvant only)
- Nivolumab + Carboplatin or Cisplatin + Pemetrexed (Neoadjuvant only)
- Osimertinib (in completely resected stage IB – IIIA EGFR [exon 19del, L858R] directly following completion of adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy)

Squamous

- Alectinib (ALK rearrangement positive; adjuvant only)
- Carboplatin + Paclitaxel ± Concurrent Radiation Therapy (RT)
- Cisplatin + Etoposide + Concurrent Radiation Therapy (RT)
- Cisplatin + Vinorelbine
- Nivolumab + Carboplatin or Cisplatin + Gemcitabine (Neoadjuvant only)
- Nivolumab + Carboplatin or Cisplatin + Paclitaxel (Neoadjuvant only)
- Osimertinib (in completely resected stage IB – IIIA EGFR [exon 19del, L858R] directly following completion of adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy)

Lung Cancer, Non-Small Cell: Consolidation: Stage III Unresectable, No Progression and PS 0–1

- Durvalumab

Lung Cancer, Non-Small Cell: Advanced/Metastatic: EGFR exon 19 deletion, L858R, S768I, L861Q, and/or G719X Mutation Positive

1st + Subsequent Lines of Therapy

- Dacomitinib
- Osimertinib
- Osimertinib + Carboplatin or Cisplatin + Pemetrexed, followed by maintenance Osimertinib ± Pemetrexed

Lung Cancer, Non-Small Cell: Advanced/Metastatic: ALK Rearrangement Positive

1st + Subsequent Lines of Therapy

- Alectinib
- Brigatinib

Lung Cancer, Non-Small Cell: Advanced/Metastatic (Excluding EGFR, ALK, RET, ROS1 and/or MET genomic aberration)

Nonsquamous: 1st Line of Therapy

- Atezolizumab (PD-L1 \geq 50% only)
- Carboplatin/Cisplatin + Paclitaxel (Immunotherapy ineligible)
- Carboplatin/Cisplatin + Pemetrexed (Immunotherapy ineligible)
- Carboplatin/Cisplatin + Pemetrexed + Pembrolizumab (PD-L1: < 1%, 1-49% and \geq 50%)
- Carboplatin/Cisplatin + Pemetrexed/Paclitaxel + Atezolizumab (PD-L1: < 1%, 1 - 49%, and \geq 50%)
- Carboplatin/Cisplatin + Pemetrexed/Paclitaxel + Cemiplimab-rwlc (PD-L1: < 1%, 1 - 49%, and \geq 50%)
- Cemiplimab-rwlc (PD-L1 \geq 50% only)
- Pembrolizumab Single Agent (PD-L1 \geq 50% only)

Nonsquamous: Maintenance

- Cemiplimab-rwlc \pm Pemetrexed
- Pembrolizumab
- Pembrolizumab + Pemetrexed
- Pemetrexed

Nonsquamous: 2nd + Subsequent Lines of Therapy

- Docetaxel
- Gemcitabine
- Pemetrexed

Squamous: 1st Line of Therapy

- Atezolizumab (PD-L1 \geq 50% only)
- Carboplatin + Paclitaxel + Cemiplimab-rwlc (PD-L1: < 1%, 1 - 49%, and \geq 50%)
- Carboplatin + Paclitaxel + Pembrolizumab (PD-L1: < 1%, 1-49% and \geq 50%)
- Carboplatin/Cisplatin + Gemcitabine (Immunotherapy ineligible)
- Carboplatin/Cisplatin + Paclitaxel (Immunotherapy ineligible)
- Cemiplimab-rwlc (PD-L1 \geq 50% only)
- Pembrolizumab Single Agent (PD-L1 \geq 50% only)

Squamous: Maintenance

- Cemiplimab-rwlc
- Pembrolizumab

Squamous: 2nd + Subsequent Lines of Therapy

- Docetaxel
- Gemcitabine

Lung Cancer, Small Cell: Limited Stage – Adjuvant or Primary Therapy

- Carboplatin + Etoposide
- Cisplatin + Etoposide
- Durvalumab

Lung Cancer, Small Cell: Extensive Stage – Adjuvant or Primary Therapy

- Carboplatin + Etoposide
- Carboplatin + Etoposide + Atezolizumab
- Carboplatin + Etoposide + Durvalumab
- Cisplatin + Etoposide
- Cisplatin + Etoposide + Durvalumab

Lung Cancer, Small Cell: Extensive Stage – Adjuvant or Primary Therapy – Maintenance

- Atezolizumab
- Durvalumab

Lung Cancer, Small Cell: Subsequent Therapy: relapse \leq 6 months

- Irinotecan
- Paclitaxel
- Tarlatamab-dlle (platinum-resistant disease)
- Topotecan IV

Lung Cancer, Small Cell: Subsequent Therapy: If prolonged disease-free interval (> 6 months)

- Carboplatin + Etoposide
- Cisplatin + Etoposide

[Back to home](#) >

Lymphoma, Classic Hodgkin (cHL)

1st Line of Therapy

- Doxorubicin + Bleomycin + Vinblastine + Dacarbazine (ABVD)
- Doxorubicin + Vinblastine + Dacarbazine (AVD)

Lymphoma, Diffuse Large B-Cell*

1st Line of Therapy

- Rituximab**-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)
- Rituximab**-DA-EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) (For Primary Mediastinal B-Cell Lymphoma (PMBCL) only)
- Rituximab**-mini-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)

Lymphoma, Diffuse Large B-Cell With Translocations of MYC and BCL2 and/or BCL6 (Double-/Triple-Hit Lymphoma)*

- Rituximab**-DA-EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin)

* Therapies that are administered at Centers of Excellence, including stem cell transplant or CAR T-cell therapy, are not included in our pathways. Patients eligible for transplant or CAR T-cell therapy should be referred appropriately for evaluation.

** Truxima and Ruxience are the preferred products for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Truxima, Ruxience and rituximab are preferred for UnitedHealthcare Medicare Advantage plan.

Lymphoma, Follicular (Grade 1-2)*

1st Line of Therapy

- Bendamustine + Rituximab** (BR)
- Rituximab** (weekly for 4 doses)

2nd + Subsequent Lines of Therapy (Non-Refractory Disease)

- Bendamustine + Rituximab** (BR)
- CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) + Rituximab**
- CVP (Cyclophosphamide, Vincristine, Prednisone) + Rituximab**
- Rituximab**

2nd + Subsequent Lines of Therapy (Refractory Disease)

- Bendamustine + Obinutuzumab
- Bendamustine + Rituximab** (BR)
- CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) + Rituximab**
- CVP (Cyclophosphamide, Vincristine, Prednisone) + Rituximab**
- Rituximab**

Lymphoma, High-Grade Follicular (Grade 3)**

1st Line of Therapy

- Rituximab**-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)

2nd + Subsequent Lines of Therapy

- Rituximab** ± GDP (Gemcitabine, Dexamethasone, Cisplatin or Carboplatin)
- Rituximab** ± ICE (Ifosfamide, Carboplatin, Etoposide)
- Rituximab** ± DHAP (Dexamethasone, Cisplatin, cytarabine)

* Therapies that are administered at Centers of Excellence, including stem cell transplant or CAR T-cell therapy, are not included in our pathways. Patients eligible for transplant or CAR T-cell therapy should be referred appropriately for evaluation.

** Truxima and Ruxience are the preferred products for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Truxima, Ruxience and rituximab are preferred for UnitedHealthcare Medicare Advantage plan.

Lymphoma, Mantle Cell*

1st Line of Therapy

- Bendamustine + Rituximab**
- Hyper-CVAD (Cyclophosphamide, Vincristine, Doxorubicin and Dexamethasone Alternating With High-Dose Methotrexate and Cytarabine) + Rituximab**
- Nordic Regimen (Dose-Intensified Induction Immunochemotherapy With Rituximab + Cyclophosphamide, Vincristine, Doxorubicin, Prednisone [Maxi-CHOP]) Alternating With Rituximab + High-Dose Cytarabine
- VR-CAP (Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone)**

Maintenance After 1st Line of Therapy

- Rituximab** (after HDT/ASCR only)

2nd Line of Therapy

- Acalabrutinib
- Bendamustine + Rituximab** (BR)
- Ibrutinib
- Zanubrutinib

3rd + Subsequent Lines of Therapy

- Acalabrutinib
- Bendamustine + Rituximab** (BR)
- Ibrutinib
- Lenalidomide
- Zanubrutinib

*Therapies that are administered at Centers of Excellence, including stem cell transplant or CAR T-cell therapy, are not included in our pathways. Patients eligible for transplant or CAR T-cell therapy should be referred appropriately for evaluation.

**Truxima and Ruxience are the preferred products for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Truxima, Ruxience and rituximab are preferred for UnitedHealthcare Medicare Advantage plan.

Lymphoma, Marginal Zone*

1st Line of Therapy

- Bendamustine + Rituximab** (BR)
- Helicobacter Pylori (H. pylori) Eradication Therapy (Gastric MALT Lymphoma only)
- Rituximab (weekly for 4 doses)

2nd + Subsequent Lines of Therapy (Non-Refractory Disease)

- Bendamustine + Rituximab** (BR)
- Chlorambucil ± Rituximab**
- CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) + Rituximab**
- CVP (Cyclophosphamide, Vincristine, Prednisone) + Rituximab**
- Rituximab (weekly for 4 doses)

2nd + Subsequent Lines of Therapy (Refractory Disease)

- Bendamustine + Obinutuzumab
- Bendamustine + Rituximab** (BR)
- Chlorambucil ± Rituximab**
- CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) + Rituximab**
- CVP (Cyclophosphamide, Vincristine, Prednisone) + Rituximab**
- Rituximab (weekly for 4 doses)

Lymphoma, High-Grade Marginal Zone (Grade 3)**

1st Line of Therapy

- Rituximab**-CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)

2nd + Subsequent Lines of Therapy

- Rituximab** ± DHAP (Dexamethasone, Cisplatin, Cytarabine)
- Rituximab** ± GDP (Gemcitabine, Dexamethasone, Cisplatin or Carboplatin)
- Rituximab** ± ICE (Ifosfamide, Carboplatin, Etoposide)

*Therapies that are administered at Centers of Excellence, including stem cell transplant or CAR T-cell therapy, are not included in our pathways. Patients eligible for transplant or CAR T-cell therapy should be referred appropriately for evaluation.

**Truxima and Ruxience are the preferred products for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Truxima, Ruxience and rituximab are preferred for UnitedHealthcare Medicare Advantage plan.

Melanoma: Neoadjuvant (Resectable; Stage III)

- Nivolumab + Ipilimumab (2 cycles)

Melanoma: Adjuvant (Resectable; Stage III)

- Nivolumab
- Pembrolizumab

Melanoma: Adjuvant (Resectable; Stage III)- (BRAF Mutated)

- Dabrafenib + Trametinib
- Nivolumab
- Pembrolizumab

Melanoma: Metastatic/Unresectable (BRAF Mutated/Symptomatic)

- Dabrafenib + Trametinib
- Vemurafenib + Cobimetinib

Melanoma: Metastatic/Unresectable (BRAF Wild Type/Mutated/Unknown)

1st + Subsequent Lines of Therapy

- Nivolumab
- Nivolumab + Ipilimumab
- Pembrolizumab

Multiple Myeloma: Primary Therapy*

Transplant Eligible

- Bortezomib + Cyclophosphamide + Dexamethasone (CyBorD or VCD)
- Bortezomib + Lenalidomide + Dexamethasone (VRD)
- Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (D-VRD)

Transplant Ineligible

- Bortezomib + Cyclophosphamide + Dexamethasone (CyBorD or VCD)
- Bortezomib + Lenalidomide + Dexamethasone (VRD)

Multiple Myeloma: Maintenance Therapy*

Transplant Eligible or Ineligible

- Bortezomib
- Lenalidomide

Multiple Myeloma: Relapsed or Refractory*

1st and 2nd Relapse

- Bortezomib + Cyclophosphamide + Dexamethasone (CyBorD or VCD)
- Bortezomib + Lenalidomide + Dexamethasone (VRD)
- Carfilzomib + Lenalidomide + Dexamethasone (KRD)
- Daratumumab + Bortezomib + Dexamethasone (DVD)
- Daratumumab + Lenalidomide + Dexamethasone (DRD)
- Daratumumab + Pomalidomide + Dexamethasone (DPD)
- Elotuzumab + Pomalidomide + Dexamethasone (EPD)
- Isatuximab-irfc + Pomalidomide + Dexamethasone (Isa-PD)
- Pomalidomide + Bortezomib + Dexamethasone (PVD)

*Therapies that are administered at Centers of Excellence, including stem cell transplant or CAR T-cell therapy, are not included in our pathways. Patients eligible for transplant or CAR T-cell therapy should be referred appropriately for evaluation.

Ovarian, Fallopian and Primary Peritoneal Cancer: Neoadjuvant Therapy

- Carboplatin + Paclitaxel*

Ovarian, Fallopian and Primary Peritoneal Cancer: Adjuvant or Primary Therapy

- Carboplatin + Paclitaxel*

Ovarian, Fallopian and Primary Peritoneal Cancer: Maintenance Therapy After Primary Therapy

- Niraparib
- Olaparib (Germline/Somatic BRCA Mutation only)

Ovarian, Fallopian and Primary Peritoneal Cancer: Platinum – Sensitive Recurrent Disease

1st + Subsequent Lines of Therapy

- Carboplatin + Gemcitabine
- Carboplatin + Liposomal Doxorubicin
- Carboplatin + Paclitaxel

Maintenance Therapy

- Niraparib
- Olaparib

Ovarian, Fallopian and Primary Peritoneal Cancer: Platinum – Resistant Recurrent Disease

1st + Subsequent Lines of Therapy

- Gemcitabine
- Liposomal Doxorubicin
- Liposomal Doxorubicin + Bevacizumab**
- Mirvetuximab soravtansine-gynx (FR α expressing tumors, \geq 75% positive tumor cells)
- Paclitaxel (weekly)
- Paclitaxel (weekly) + Bevacizumab**
- Tamoxifen

* Only intravenous carboplatin + paclitaxel are pathway regimens.

** Mvasi[®] is the preferred medication for most UnitedHealthcare Community Plans and UnitedHealthcare commercial plans. Mvasi and bevacizumab are preferred for UnitedHealthcare Medicare Advantage plan.

Pancreatic Cancer: Neoadjuvant (Resectable/Borderline Resectable)

- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (FOLFIRINOX/mFOLFIRINOX)
- Gemcitabine + Albumin-Bound Paclitaxel (G-nP)

Pancreatic Cancer: Adjuvant (Resectable)

Pancreatic Cancer: Adjuvant (Resectable)

- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (mFOLFIRINOX)
- Gemcitabine + Capecitabine
- Gemcitabine

Pancreatic Cancer: Locally Advanced/Metastatic

1st Line of Therapy

- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (FOLFIRINOX/mFOLFIRINOX)
- Gemcitabine + Albumin-Bound Paclitaxel (G-nP)
- Gemcitabine

2nd + Subsequent Lines of Therapy

- Gemcitabine + Albumin-Bound Paclitaxel (G-nP)
- Gemcitabine
- Fluorouracil/Leucovorin
- Fluorouracil/Leucovorin + Oxaliplatin (OFF)
- Fluorouracil/Leucovorin + Oxaliplatin (FOLFOX)
- Fluorouracil/Leucovorin + Irinotecan (FOLFIRI)
- Fluorouracil/Leucovorin + Oxaliplatin + Irinotecan (FOLFIRINOX/mFOLFIRINOX)

Prostate Cancer

Adjuvant/Neoadjuvant; Castration-sensitive disease

- Goserelin
- Leuprolide
- Triptorelin

Recurrent/Metastatic; Castration-sensitive disease

- Goserelin ± Abiraterone/Prednisone ± docetaxel
- Leuprolide ± Abiraterone/Prednisone ± docetaxel
- Triptorelin ± Abiraterone/Prednisone ± docetaxel

Recurrent/Metastatic; Castration-resistant disease

- Goserelin + Cabazitaxel (after prior docetaxel therapy)
- Goserelin + Enzalutamide (after prior abiraterone therapy)
- Goserelin ± Abiraterone/Prednisone or docetaxel
- Leuprolide + Cabazitaxel (after prior docetaxel therapy)
- Leuprolide + Enzalutamide (after prior abiraterone therapy)
- Leuprolide ± Abiraterone/Prednisone or docetaxel
- Olaparib + abiraterone (BRCA1/2 mutations positive)
- Olaparib + abiraterone (Homologous recombination repair (HRR) mutations positive)
- Triptorelin + Cabazitaxel (after prior docetaxel therapy)
- Triptorelin + Enzalutamide (after prior abiraterone therapy)
- Triptorelin ± Abiraterone/Prednisone or docetaxel

List of updates

Date	Changes
Jan. 1, 2024	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Esophageal and Esophagogastric Cancer <ul style="list-style-type: none"> - Added Pembrolizumab + fluoropyrimidine + oxaliplatin or cisplatin (PD-L1 CPS ≥ 10) to Recurrent/Metastatic/Unresectable locally advanced disease; 1st line of therapy HER2-negative or Unknown • Gastric Cancer <ul style="list-style-type: none"> - Added Pembrolizumab + fluoropyrimidine + oxaliplatin or cisplatin (PD-L1 CPS ≥ 10) to Recurrent/Metastatic/Unresectable locally advanced disease; 1st line of therapy HER2-negative or Unknown
March 1, 2024	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Non-Small Cell Lung Cancer <ul style="list-style-type: none"> - Added Carboplatin + Pemetrexed ± Concurrent RT to Neoadjuvant/Adjuvant, nonsquamous - Added Nivolumab + Carboplatin or Cisplatin + Paclitaxel and Nivolumab + Carboplatin or Cisplatin + Pemetrexed (Neoadjuvant only) to Neoadjuvant/Adjuvant, nonsquamous - Added Nivolumab + Carboplatin or Cisplatin + Paclitaxel and Nivolumab + Carboplatin or Cisplatin + Gemcitabine (Neoadjuvant only) to Neoadjuvant/Adjuvant, squamous - Added Carboplatin/Cisplatin + Paclitaxel and Carboplatin/Cisplatin + Pemetrexed (immunotherapy ineligible) to Advanced/Metastatic - Nonsquamous (EGFR, ALK, RET WT), 1st line of therapy - Added Carboplatin/Cisplatin + Paclitaxel and Carboplatin/Cisplatin + Gemcitabine (immunotherapy ineligible) to Advanced/Metastatic - Squamous (EGFR, ALK, RET WT), 1st line of therapy - Added Gemcitabine to Advanced/Metastatic - Nonsquamous/Squamous, 2nd + subsequent lines of therapy • Prostate Cancer <ul style="list-style-type: none"> - Added Olaparib + abiraterone (BRCA1/2 mutations positive) and Olaparib + abiraterone (Homologous recombination repair (HRR) mutations positive) to Recurrent/Metastatic; Castration-resistant disease • Small Cell Lung Cancer <ul style="list-style-type: none"> - Removed Paclitaxel from pathways as Subsequent Therapy: Relapse > 6 months

List of updates

Date	Changes
May 1, 2024	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Biliary Tract Cancers <ul style="list-style-type: none"> - Removed Gemcitabine + Cisplatin + Durvalumab from pathways for Unresectable/Metastatic; 1st Line of Therapy • Chronic Myeloid Leukemia <ul style="list-style-type: none"> - Removed Omacetaxine (T315I mutation only) from pathways for 2nd + Subsequent Lines of Therapy - Added Dasatinib, Imatinib, Nilotinib, and T315I mutation only comment to Ponatinib to pathways for 2nd + Subsequent Lines of Therapy - Added Asciminib to pathways for 3rd + Subsequent Lines of Therapy • Hepatocellular Carcinoma <ul style="list-style-type: none"> - Removed Lenvatinib and Sorafenib from pathways for Unresectable, Not a Transplant Candidate, Metastatic Disease, Inoperable by PS or Comorbidity; 1st Line of Therapy - Removed Atezolizumab + Bevacizumab from pathways for Unresectable, Not a Transplant Candidate, Metastatic Disease, Inoperable by PS or Comorbidity; 2nd + Subsequent Lines of Therapy • Pancreatic Cancer <ul style="list-style-type: none"> - Added Fluorouracil/Leucovorin and Capecitabine to pathways for Locally Advanced/Metastatic; Maintenance • Multiple Myeloma <ul style="list-style-type: none"> - Removed Bortezomib + Thalidomide + Dexamethasone (VTD) from pathways for Primary Therapy; Transplant Eligible - Added Daratumumab + Bortezomib + Lenalidomide + Dexamethasone (D-VRD) to pathways for Primary Therapy; Transplant Eligible - Removed Isatuximab-irfc + Pomalidomide + Dexamethasone (Isa-PD) from pathways for Relapsed or Refractory; 1st Relapse - Added Daratumumab + Pomalidomide + Dexamethasone (DPD) to pathways for Relapsed or Refractory; 2nd Relapse

List of updates

Date	Changes
<p>Aug. 1, 2024</p>	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Head and Neck Cancer <ul style="list-style-type: none"> - Added Carboplatin + Paclitaxel + Pembrolizumab (for combined positive score (CPS) ≥ 1 only) to pathways for Non-Nasopharyngeal: 1st Line of Therapy - Added Cisplatin + Gemcitabine + Toripalimab-tpzi to pathways for Nasopharyngeal: 1st Line of Therapy • Kidney Cancer <ul style="list-style-type: none"> - Added Pembrolizumab to pathways for Adjuvant therapy - Added Nivolumab + Ipilimumab to pathways for Relapsed or Metastatic (Clear Cell): 1st Line of Therapy • Follicular Lymphoma <ul style="list-style-type: none"> - Added Rituximab (weekly for 4 doses) to pathways for 1st Line of Therapy • Mantle Cell Lymphoma <ul style="list-style-type: none"> - Removed Alternating RCHOP/RDHAP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone)/(Rituximab, Dexamethasone, Cytarabine, Cisplatin) from pathways for 1st Line of Therapy • Marginal Zone Lymphoma <ul style="list-style-type: none"> - Removed Chlorambucil \pm Rituximab from pathways for 1st Line of Therapy
<p>Sept. 1, 2024</p>	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Breast Cancer <ul style="list-style-type: none"> - Reformatted Metastatic and Recurrent - Chemotherapy HER2 Negative - Added Sacituzumab Govitecan-hziy (HR+, HER2-) to Metastatic and Recurrent - Chemotherapy HER2 Negative: 1st + Subsequent Lines of Therapy - Added Tucatinib + Trastuzumab + Capecitabine (in patients with brain mets) to Metastatic and Recurrent - Chemotherapy, HER2 Positive: 2nd + Subsequent lines of therapy - Added Tucatinib + Trastuzumab + Capecitabine to Metastatic and Recurrent - Chemotherapy, HER2 Positive: 3rd + Subsequent lines of therapy • Chronic Lymphocytic Leukemia/Small Lymphocytic (CLL/SLL) <ul style="list-style-type: none"> - Removed Zanubrutinib from pathways • Melanoma <ul style="list-style-type: none"> - Added Nivolumab + Ipilimumab (2 cycles) to Neoadjuvant therapy

List of updates

Date	Changes
<p>March 1, 2025</p>	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Breast Cancer <ul style="list-style-type: none"> - Added Pembrolizumab + Carboplatin + Paclitaxel, followed by Pembrolizumab + Cyclophosphamide + Doxorubicin or Epirubicin, followed by adjuvant Pembrolizumab (for high-risk TNBC only) to Neoadjuvant/Adjuvant; HER2 Negative - Added Pembrolizumab (continuation in TNBC following pembrolizumab + chemotherapy to Adjuvant (Residual Disease Post-Neoadjuvant Treatment); Triple Negative Breast Cancer • Lung Cancer, Small Cell <ul style="list-style-type: none"> - Added Durvalumab to Limited Stage (Adjuvant or Primary) • Lung Cancer, Non-Small Cell <ul style="list-style-type: none"> - Added Alectinib (ALK rearrangement positive; adjuvant only) to Lung Cancer, Non-Small Cell: Neoadjuvant/Adjuvant - Advanced/Metastatic: Changed (EFFF, ALK, RET Wild Type) to (Excluding EGFR, ALK, RET, ROS1 and/or MET genomic aberration)
<p>June 1, 2025</p>	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Chronic Myeloid Leukemia (CML) <ul style="list-style-type: none"> - Removed Ponatinib (T315I only) from '2nd + subsequent lines of therapy' - Added Asciminib (T315I only) to '2nd + subsequent lines of therapy' • Hepatobiliary Cancers <ul style="list-style-type: none"> - Removed Unresectable, Not a Transplant Candidate, Metastatic Disease, Inoperable by PS or Comorbidity, 2nd + subsequent lines of therapy from pathways - Added Gemcitabine + Cisplatin + Durvalumab and Gemcitabine + Cisplatin + Pembrolizumab to Biliary Tract Cancers (Gallbladder, Intrahepatic and Extrahepatic Cholangiocarcinoma): Unresectable/Metastatic, 1st Line of therapy • Multiple Myeloma <ul style="list-style-type: none"> - Consolidated 1st and 2nd relapse pathways for Relapsed or Refractory disease • Pancreatic cancer <ul style="list-style-type: none"> - Removed Maintenance from Pancreatic Cancer: Locally Advanced/Metastatic

List of updates

Date	Changes
Sept 1, 2025	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Head and Neck Cancers <ul style="list-style-type: none"> - Removed '(for combined positive score (CPS) \geq 1 for regimens 'Carboplatin + Paclitaxel + Pembrolizumab' and 'Cisplatin or Carboplatin + Fluorouracil (5FU) + Pembrolizumab' • Kidney Cancer <ul style="list-style-type: none"> - Removed 'Relapsed or Metastatic (Clear Cell): 2nd + Subsequent lines of therapy' from pathways • Hodgkin Lymphoma <ul style="list-style-type: none"> - Removed 'Escalated bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone (escBEACOPP)' from pathways • Diffuse Large B-Cell Lymphoma <ul style="list-style-type: none"> - Removed '2nd + Subsequent Lines of Therapy' from pathways
Dec. 1, 2025	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Bladder Cancer <ul style="list-style-type: none"> - Added 'Enfortumab vedotin-ejfv + Pembrolizumab' under Bladder Cancer: Locally Advanced or Metastatic: 1st Line of Therapy • Breast Cancer <ul style="list-style-type: none"> - Added 'Inavolisib + palbociclib + fulvestrant (PIK3CA activating mutations)' under Breast Cancer Metastatic and Recurrent - Endocrine Therapy; HER2 NEGATIVE;; 1st Line of Therapy - Removed 'Metastatic (Endocrine therapy) - HER2 positive' - Remove 3rd + Subsequent Lines of Therapy: Sacituzumab Govitecan-hziy (for mTNBC)' - Added Sacituzumab Govitecan-hziy (for mTNBC) under 'Metastatic - (Chemotherapy) - HER2 Negative'; 2nd+ Subsequent Lines of Therapy' - Added the following new section under Metastatic - HER2 Positive', under 1stline of therapy: • 1st+ Subsequent lines of therapy <ul style="list-style-type: none"> - AI + Trastuzumab (HR+) - AI + Lapatinib (HR+) - Removed Ado-trastuzumab emtansine under Metastatic - HER2 Positive, - Added Ado-trastuzumab emtansine under '3rd+ Subsequent lines of therapy' - Remove these regimens: <ul style="list-style-type: none"> ◦ Capecitabine + Lapatinib ◦ Capecitabine + Trastuzumab* ◦ Gemcitabine + Trastuzumab* ◦ Paclitaxel + Trastuzumab ◦ Vinorelbine + Trastuzumab

List of updates

Date	Changes
Dec. 1, 2025 (cont.)	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • 1st+ Subsequent lines of therapy (cont.) <ul style="list-style-type: none"> - Add the following new section - 4th + subsequent lines of therapy <ul style="list-style-type: none"> ◦ Trastuzumab + Paclitaxel ◦ Trastuzumab + Vinorelbine ◦ Trastuzumab + Gemcitabine ◦ Trastuzumab + Capecitabine • Colon/Rectal Cancer: <ul style="list-style-type: none"> - Added Fluorouracil + Leucovorin + Oxaliplatin (FOLFOX)+ Encorafenib + Panitumumab or Cetuximab* (BRAF V600E mut+; 1st line only) under Colon/Rectal Cancer: Metastatic KRAS/NRAS/BRAF: Wild Type 1st + Subsequent Lines of Therapy - Remove section '2nd+ subsequent lines of therapy' <ul style="list-style-type: none"> ◦ Encorafenib + Cetuximab (BRAF V600E mutation positive) ◦ Encorafenib + Panitumumab (BRAF V600E mutation positive) - Updated heading 'Colon/Rectal Cancer: Metastatic MSI-H/dMMR' to Colon/Rectal • Cancer: Metastatic MSI-H/dMMR or POLE/POLD1 mutation <ul style="list-style-type: none"> - Added Nivolumab + Ipilimumab followed by Nivolumab maintenance • Esophageal and Esophagogastric Cancers: Under Recurrent/Metastatic/Unresectable locally advanced disease; 1st line of therapy; HER2-negative or Unknown replaced the regimens with: <ul style="list-style-type: none"> - Capecitabine + Cisplatin - Capecitabine + Cisplatin + Nivolumab (squamous cell carcinoma and CPS ≥ 1) - Capecitabine + Oxaliplatin - Capecitabine + Oxaliplatin + Nivolumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Capecitabine + Cisplatin + Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Capecitabine + Oxaliplatin + Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Capecitabine + Cisplatin + Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Capecitabine + Oxaliplatin + Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Fluorouracil ± Leucovorin + Cisplatin - Fluorouracil ± Leucovorin + Cisplatin + Nivolumab (squamous cell carcinoma and CPS ≥ 1)

List of updates

Date	Changes
<p>Dec. 1, 2025 (cont.)</p>	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> - Fluorouracil ± Leucovorin + Oxaliplatin - Fluorouracil ± Leucovorin + Oxaliplatin + Nivolumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Fluorouracil ± Leucovorin + Cisplatin+ Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Fluorouracil ± Leucovorin + Oxaliplatin + Pembrolizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Fluorouracil ± Leucovorin + Cisplatin+ Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) - Fluorouracil ± Leucovorin + Oxaliplatin + Tislelizumab (for adenocarcinoma and PD-L1 CPS ≥ 5 or squamous cell carcinoma CPS ≥ 1) <ul style="list-style-type: none"> • Gastric Cancers: <ul style="list-style-type: none"> - Under Recurrent/Metastatic/Unresectable locally advanced disease; 1st line of therapy; HER2-negative or Unknown - Replaced the regimens with: <ul style="list-style-type: none"> ◦ Capecitabine + Cisplatin or Oxaliplatin ◦ Capecitabine + Oxaliplatin + Nivolumab (for PD-L1 CPS ≥ 5) ◦ Capecitabine + Cisplatin or Oxaliplatin + Pembrolizumab (PD-L1 CPS ≥ 5) ◦ Capecitabine + Cisplatin or Oxaliplatin + Tislelizumab (PD-L1 CPS ≥ 5) ◦ Fluorouracil ± Leucovorin + Cisplatin or Oxaliplatin ◦ Fluorouracil ± Leucovorin + Oxaliplatin + Nivolumab (for PD-L1 CPS ≥ 5) ◦ Fluorouracil ± Leucovorin + Cisplatin or Oxaliplatin + Pembrolizumab (PD-L1 CPS ≥ 5) ◦ Fluorouracil ± Leucovorin + Cisplatin or Oxaliplatin + Tislelizumab (PD-L1 CPS ≥ 5) - Removed Capecitabine + Cisplatin under ‘Perioperative’ • Endometrial Cancer <ul style="list-style-type: none"> - Removed section – Metastatic or Recurrent; 2nd + Subsequent Lines of Therapy <ul style="list-style-type: none"> ◦ Docetaxel ◦ Doxorubicin ◦ Lenvatinib + Pembrolizumab (for pMMR tumors after prior platinum-based therapy, including neoadjuvant and adjuvant) ◦ Liposomal Doxorubicin ◦ Paclitaxel • Recurrent/Metastatic/Unresectable locally advanced disease; 1st line of therapy HER2-negative or Unknown <ul style="list-style-type: none"> - Added Cisplatin or Oxaliplatin + Paclitaxel + Tislelizumab (squamous cell carcinoma CPS ≥ 1)

List of updates

Date	Changes
March 1, 2026	<p>Updates to existing pathways</p> <ul style="list-style-type: none"> • Breast Cancer <ul style="list-style-type: none"> - Moved Fam-trastuzumab deruxtecan–nxki and Sacituzumab Govitecan-hziy from Breast Cancer: Metastatic and Recurrent – Chemotherapy HER2 NEGATIVE: 2nd + Subsequent Lines of Therapy to Breast Cancer: Metastatic and Recurrent – Chemotherapy HER2 NEGATIVE: 1st + Subsequent Lines of Therapy - Added Docetaxel + Carboplatin + Trastuzumab + Pertuzumab (TCHP) (stage IIA+) to Neoadjuvant/Adjuvant – HER2 Positive. • Small Cell Lung Cancer <ul style="list-style-type: none"> - Added Tarlatamab-dlle (platinum-resistant disease) under Lung Cancer, Small Cell: Subsequent Therapy: Relapse ≤ 6 months - Updated Lung Cancer, Small Cell: Subsequent Therapy: Relapse ≤ 6 months to Lung Cancer, Small Cell: Subsequent Therapy: If prolonged disease-free interval (>6 months) - Removed Irinotecan and Topotecan IV from Lung Cancer, Small Cell: Subsequent Therapy: If prolonged disease-free interval (>6 months) • Non-Small Cell Lung Cancer <ul style="list-style-type: none"> - Added Nivolumab + Cisplatin + Docetaxel and removed Nivolumab + Cisplatin + Paclitaxel from Lung Cancer, Non-Small Cell: Neoadjuvant /Adjuvant, Nonsquamous - Added Osimertinib + Carboplatin or Cisplatin + Pemetrexed, followed by maintenance Osimertinib ± Pemetrexed under Lung Cancer, Non-Small Cell: Advanced/Metastatic: EGFR exon 19 deletion, L858R, S768I, L861Q, and/or G719X Mutation Positive, 1st + Subsequent Lines of Therapy - Added Carboplatin/Cisplatin + Pemetrexed/Paclitaxel + Atezolizumab (PDL1: <1%, 1 - 49%, and ≥ 50%) under Lung Cancer, Non-Small Cell: Advanced/Metastatic (Excluding EGFR, ALK, RET, ROS1 and/or MET genomic aberration), Nonsquamous: 1st Line of Therapy

Insurance coverage provided by or through UnitedHealthcare Insurance Company or its affiliates. Health plan coverage provided by UnitedHealthcare of Arizona, Inc., UHC of California DBA UnitedHealthcare of California, UnitedHealthcare Benefits Plan of California, UnitedHealthcare of Colorado, Inc., UnitedHealthcare of the Mid-Atlantic, Inc., MAMSI Life and Health Insurance Company, UnitedHealthcare of New York, Inc., UnitedHealthcare Insurance Company of New York, UnitedHealthcare of Oklahoma, Inc., UnitedHealthcare of Oregon, Inc., UnitedHealthcare of Pennsylvania, Inc., UnitedHealthcare of Texas, Inc., UnitedHealthcare Benefits of Texas, Inc., UnitedHealthcare of Utah, Inc., UnitedHealthcare of Washington, Inc., Optimum Choice, Inc., Oxford Health Insurance, Inc., Oxford Health Plans (NJ), Oxford Health Plans (CT), Inc., All Savers Insurance Company, Tufts Health Freedom Insurance Company or other affiliates. Administrative services provided by OptumHealth Care Solutions, LLC, OptumRx, Oxford Health Plans LLC, United HealthCare Services, Inc., Tufts Health Freedom Insurance Company or other affiliates. Behavioral health products provided by U.S. Behavioral Health Plan, California (USBHPC), United Behavioral Health (UBH), or its affiliates.

